Related Experiment Video
Updated: Dec 19, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
MiR-181a reduces radiosensitivity of non-small-cell lung cancer via inhibiting PTEN
Yanfen Chen1, Wenjiang Liao1, Anhui Yuan1
1Department of Pediatrics, Zhongshan Guzhen People's Hospital, Zhongshan, China.
Background:
The aim of this study is to explore the effect of micro ribonucleic acid (miR)-181a on the radiosensitivity of non-small cell lung cancer (NSCLC) and its potential mechanism of action.
Methods:
The differentially expressed miRNAs were screened in lung cancer tissues of radiotherapy-resistant and non-radiotherapy-resistant NSCLC patients, and verified via reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Next, the effects of different miRNA expressions on patients' survival time were discussed, and target genes of miR-181a were predicted. The effect of miR-181a expression on radiosensitivity was determined using cell counting kit-8 (CCK-8) assay and flow cytometry. The direct target of miR-181a was verified via luciferase reporter assay. Phosphatase and tensin homolog deleted on chromosome ten (PTEN) was overexpressed using lentiviruses, and then whether miR-181a reduces radiosensitivity via targeting PTEN was detected via CCK-8 assay and flow cytometry. Finally, Western blotting was performed to detect the protein expression of PTEN.
Results:
The screening results of microarray expression profile assay revealed that 15 miRNAs had significant differences in lung cancer tissues of radiotherapy-resistant NSCLC patients compared with those in non-radiotherapy-resistant NSCLC patients. The results of RT-qPCR showed that hsa-miR-181a, hsa-miR-199b, hsa-miR-489 and hsa-miR-589 were significantly up-regulated in the lung cancer tissues of radiotherapy-resistant NSCLC patients compared with those in non-radiotherapy-resistant NSCLC patients. In addition, it was found that the survival time of NSCLC patients was obviously prolonged in hsa-miR-181a low-expression group and hsa-miR-589 high-expression group, but hsa-miR-489 and hsa-miR-199b had no significant influence on the survival time of NSCLC patients. According to KEGG enrichment analysis, the target genes of miR-181a were evidently enriched in the phosphatidylinositol 3-hydroxy kinase (PI3K)/protein kinase B (AKT) signaling pathway, NSCLC signaling pathway and other cancer signaling pathways. Under the radiation dose of 2, 4, 6 and 8 Gy, the survival rate of A549 cells rose in miR-181a mimic group, but declined in miR-181a inhibitor group. Moreover, compared with that in model group, the radiotherapy-induced apoptosis was markedly inhibited in miR-181a mimic group, but markedly promoted in miR-181a inhibitor group. It was also observed that the response of cells to radiotherapy-induced apoptosis was remarkably weakened in miR-181a mimic + PTEN overexpression group compared with that in miR-181a mimic group. Finally, miR-181a mimic group had a significantly lower protein expression of PTEN and significantly higher protein expressions of CXC chemokine receptor 4 (CXCR4), phosphorylated signal transducer and activator of transcription 3 (p-STAT3), p-AKT1 and p-mammalian target of rapamycin (mTOR) than model group, while miR-181a inhibitor group had the opposite protein expressions. The protein expressions of CXCR4, p-STAT3, p-AKT1 and p-mTOR were obviously lower in miR-181a mimic + PTEN overexpression group than those in miR-181a mimic group.
Conclusions:
MiR-181a reduces the radiosensitivity of NSCLC via inhibiting PTEN expression.
Insights
Micro ribonucleic acid (miR)-181a decreases non-small cell lung cancer (NSCLC) radiosensitivity by inhibiting phosphatase and tensin homolog deleted on chromosome ten (PTEN). This finding offers potential therapeutic targets for improving NSCLC radiotherapy outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Radiotherapy Research
Background:
- Non-small cell lung cancer (NSCLC) exhibits variable responses to radiotherapy.
- Understanding the molecular mechanisms underlying radioresistance is crucial for improving treatment efficacy.
- MicroRNAs (miRNAs) are implicated as regulators of cancer progression and treatment response.
Purpose of the Study:
- To investigate the role of micro ribonucleic acid (miR)-181a in the radiosensitivity of NSCLC.
- To elucidate the potential molecular mechanism by which miR-181a affects NSCLC radiosensitivity.
- To identify potential therapeutic targets for enhancing NSCLC radiotherapy.
Main Methods:
- Differential expression analysis of miRNAs in radiotherapy-resistant versus non-resistant NSCLC tissues.
- Validation of miRNA expression using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
- Functional assays (cell counting kit-8, flow cytometry, luciferase reporter assay) to assess miR-181a's effect on radiosensitivity and its target.
- Overexpression of phosphatase and tensin homolog deleted on chromosome ten (PTEN) to confirm the targeting mechanism.
- Western blotting to analyze protein expression levels of key signaling molecules.
Main Results:
- Hsa-miR-181a was significantly upregulated in radiotherapy-resistant NSCLC tissues.
- Low miR-181a expression correlated with prolonged patient survival.
- miR-181a mimic increased NSCLC cell survival and inhibited apoptosis post-irradiation, while miR-181a inhibitor promoted apoptosis.
- miR-181a targets PTEN, and its radiosensitizing effect is mediated through PTEN inhibition, impacting the PI3K/AKT pathway.
Conclusions:
- Micro ribonucleic acid (miR)-181a significantly reduces the radiosensitivity of non-small cell lung cancer (NSCLC).
- The mechanism involves the inhibition of phosphatase and tensin homolog deleted on chromosome ten (PTEN) expression.
- Targeting miR-181a or its downstream pathways presents a potential strategy to enhance NSCLC radiosensitivity.
Related Concept Videos
MicroRNAs
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...

